SCHEMBL22290358

SCHEMBL22290358

CC(C)(C)n1ccc(C(=O)NCC(=O)Nc2nc(-c3cccc(N4CCOCC4)c3)cs2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PHGDH O43175 2/20 0.48
▸ POLB P06746 1/20 0.45
▸ KDM1A O60341 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ ALK Q9UM73 4/20 0.44
▸ CSNK1D P48730 1/20 0.43
▸ RAB9A P51151 2/20 0.42
▸ MAPT P10636 4/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ MAPK1 P28482 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ RAF1 P04049 1/20 0.42
▸ MAPK14 Q16539 1/20 0.42
▸ KMT2A Q03164 5/20 0.41
▸ MMP2 P08253 1/20 0.41
▸ MMP8 P22894 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ CYP1A1 P04798 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31173227 1.00 PHGDH (0.48) PHGDHPOLBKDM1AHDAC1ALK
SCHEMBL22290773 0.90 PHGDH (0.39) PHGDHPOLBKDM1AHDAC1ALK
SCHEMBL22290791 0.88 SMARCA2 (0.44) PHGDHHDAC1ALKRAB9AMAPT
SCHEMBL22290793 0.88 SMARCA2 (0.44) PHGDHHDAC1ALKRAB9AMAPT
SCHEMBL22290695 0.87 PHGDH (0.51) PHGDHPOLBKDM1AHDAC1ALK
SCHEMBL22305488 0.87 PHGDH (0.49) PHGDHPOLBKDM1AHDAC1ALK
SCHEMBL31173199 0.87 PHGDH (0.51) PHGDHPOLBKDM1AHDAC1ALK
SCHEMBL22306593 0.87 CYP3A4 (0.42) PHGDHPOLBALKCSNK1DRAB9A
SCHEMBL22306234 0.85 HDAC3 (0.52) HDAC1MAPT
SCHEMBL22305493 0.84 MAPT (0.47) PHGDHPOLBHDAC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 — — US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 — — EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 — — CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB PHGDH 3520/4885POLB 165/4885KDM1A 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback